The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients
暂无分享,去创建一个
Hong-Yang Wang | L. Du | Chuanxin Wang | Jingfeng Liu | Jing Zhang | J. Hou | Lei Chen | Yuan Yang | Yanhang Gao | H. Wen | Yingchao Wang | He-ping Hu | Jian Sun | F. Shen | Bo Zheng | G. Deng | Xiao-Long Liu | R. Fan | Yuanda Gao | Huadong Yan | F. Kong | Min-feng Liang | Gao Liu | J. Bai | Hui Wang | Dan Zheng | J. Xia | Xiao-tang Fan | Yunsong Qian | Guoqing Jiang | Chun-ying Wang | Yi-nong Ye | Qing-Zheng Zhang | Lan-Lan Ru | Yanlong Yu | Fuming Sun | Chunxiu Zhong | Yin Wang | Jin-Ming Chen | Lin Wu | Ying-chao Wang | Yan-hang Gao | Chuanqi Wang | Lutao Du | Yu-Jing Gao
[1] G. Abou-Alfa,et al. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients , 2021, Cell Research.
[2] M. Odenthal,et al. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma , 2020, International journal of biological sciences.
[3] N. Giama,et al. Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA , 2019, Theranostics.
[4] Wei Zhang,et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma , 2019, Gut.
[5] Zhibin Hu,et al. HBV mutations in EnhII/BCP/PC region contribute to the prognosis of hepatocellular carcinoma , 2019, Cancer medicine.
[6] B. Chabner,et al. Application of Cell-free DNA Analysis to Cancer Treatment. , 2018, The New England journal of medicine.
[7] Y. Dor,et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease , 2018, bioRxiv.
[8] S. Urban,et al. Cellular Genomic Sites of Hepatitis B Virus DNA Integration , 2018, Genes.
[9] Nikhil Wagle,et al. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Long-xia Wang,et al. A quantitative cSMART assay for noninvasive prenatal screening of autosomal recessive nonsyndromic hearing loss caused by GJB2 and SLC26A4 mutations , 2017, Genetics in Medicine.
[11] Xiuqing Zhang,et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma , 2016, Nature Communications.
[12] Reza Assadi,et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.
[13] Ryan D. Morin,et al. Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies , 2016, Molecular Cancer Research.
[14] T. Tsunoda,et al. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy , 2015, Cellular and molecular gastroenterology and hepatology.
[15] Martin E. Gleave,et al. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.
[16] D. Hoon,et al. Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients , 2013, Expert review of molecular diagnostics.
[17] Angela M. Liu,et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma , 2012, Nature Genetics.
[18] G. Cao,et al. Association Between the Various Mutations in Viral Core Promoter Region to Different Stages of Hepatitis B, Ranging of Asymptomatic Carrier State to Hepatocellular Carcinoma , 2011, The American Journal of Gastroenterology.
[19] John D. Groopman,et al. Prospective Evaluation of Hepatitis B 1762T/1764A Mutations on Hepatocellular Carcinoma Development in Shanghai, China , 2009, Cancer Epidemiology Biomarkers & Prevention.
[20] C. Sabin,et al. HBV A1762T, G1764A Mutations Are a Valuable Biomarker for Identifying a Subset of Male HBsAg Carriers at Extremely High Risk of Hepatocellular Carcinoma: A Prospective Study , 2008, The American Journal of Gastroenterology.
[21] Chien-Jen Chen,et al. Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma , 2008, Journal of the National Cancer Institute.
[22] F. Zoulim,et al. Hepatitis B virus genetic variability and evolution. , 2007, Virus research.
[23] P. Vineis,et al. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. , 2007, Mutation research.
[24] C. Bréchot,et al. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). , 2000, Seminars in cancer biology.
[25] D. Liang,et al. Noninvasive prenatal testing for Wilson disease by use of circulating single-molecule amplification and resequencing technology (cSMART). , 2015, Clinical chemistry.
[26] Lanjuan Li,et al. The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis. , 2009, Journal of hepatology.
[27] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.